Actively Recruiting
Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer
Led by National Cancer Center, Korea · Updated on 2025-09-12
80
Participants Needed
1
Research Sites
433 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To compare outcomes between the CRS group and the control group in patients with recurrent epithelial ovarian cancer who have undergone chemotherapy
CONDITIONS
Official Title
Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with histologically confirmed epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer
- Patients with recurrent ovarian cancer who have received 3 or 4 cycles of platinum-based chemotherapy and were deemed unsuitable for secondary cytoreductive surgery due to a negative AGO score
- Patients with recurrent ovarian cancer who have responded to chemotherapy (complete response, partial response, or stable disease)
- Disease must be platinum-sensitive with recurrence more than 6 months after last platinum therapy
- Patients aged 19 years or older who provide informed written consent
- ECOG Performance Status of 0-2 within 28 days prior to trial allocation
- Women medically unable to conceive or agreeing to contraception during treatment if of childbearing potential
- Adequate organ function including bone marrow, renal, liver, heart, and lung function as defined by specific laboratory and clinical criteria
- Consent to secondary use of clinical information for future biomedical research (optional)
You will not qualify if you...
- Patients with non-epithelial ovarian cancer or borderline ovarian tumors
- Patients unsuitable for platinum-based chemotherapy
- Patients over 80 years old
- Life expectancy less than 3 months
- Unsuitable for secondary cytoreductive surgery due to clinical findings such as severe adhesions, bowel obstruction, or other conditions making surgery infeasible
- Inadequate cardiac, pulmonary, hepatic, renal, or bone marrow function for surgery
- Uncontrolled active infections
- Diagnosis of myelodysplastic syndrome or acute myeloid leukemia
- Primary disease outside the abdomen expected to cause major morbidity or mortality
- Active central nervous system metastasis or carcinomatous meningitis; history of brain metastasis must be stable
- Infections requiring systemic treatment
- Uncontrolled active tuberculosis within one month before treatment
- Psychiatric disorders interfering with compliance
- Positive urine pregnancy test within 14 days prior to allocation for women of childbearing potential
- Currently breastfeeding
- History of allogeneic tissue/solid organ or bone marrow transplantation
- Unlikely to comply with trial procedures as judged by investigator
- Currently enrolled in another clinical trial receiving investigational drugs or devices or used such within 3 weeks prior to study treatment
- Patients in follow-up phase of clinical trial may participate only if 3 weeks have passed since last investigational drug or device use
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
National Cancer Center, Korea
Goyang-si, Gyeonggi-do, South Korea, 10408
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here